DomperidoneThird Party Manufacturing in India

Domperidone is a peripherally acting dopamine D2 and D3 receptor antagonist with both antiemetic and prokinetic properties. Unlike metoclopramide, domperidone does not readily cross the blood-brain barrier, which significantly reduces the risk of central nervous system side effects such as extrapyramidal reactions. Its antiemetic effect is mediated through antagonism of dopamine D2 receptors in the chemoreceptor trigger zone (CTZ) located in the area postrema of the medulla oblongata, a region that lies outside the blood-brain barrier and is accessible to circulating domperidone. By blocking dopamine receptors in the CTZ, domperidone suppresses the signals that trigger nausea and vomiting. In addition to its central antiemetic action, domperidone exerts a prokinetic effect on the upper gastrointestinal tract. It increases lower esophageal sphincter pressure, improves antroduodenal coordination, and accelerates gastric emptying by blocking inhibitory dopamine receptors in the gastric and duodenal smooth muscle. This prokinetic action enhances gastric motility and reduces symptoms of dyspepsia such as epigastric fullness, bloating, and abdominal discomfort. Domperidone also causes a rise in serum prolactin levels by blocking the inhibitory effect of dopamine on prolactin secretion from the pituitary gland. This dual mechanism makes domperidone an effective treatment for nausea, vomiting, and gastric motility disorders.

Therapeutic Uses

Domperidone is prescribed for the treatment of:

• Nausea and Vomiting: For the symptomatic relief of acute nausea and vomiting of various causes, including drug-induced nausea (particularly from dopaminergic Parkinson's medications), postoperative nausea, and functional dyspepsia.
• Gastroparesis: For improving gastric emptying and reducing symptoms in patients with diabetic, idiopathic, or postsurgical gastroparesis, including early satiety, postprandial fullness, bloating, and epigastric pain.
• Gastroesophageal Reflux Disease (GERD): As an adjunct to acid-suppressive therapy in patients with delayed gastric emptying contributing to reflux symptoms.
• Dyspepsia: For the symptomatic treatment of the dyspeptic symptom complex associated with delayed gastric emptying, including epigastric sense of fullness, abdominal distension, and epigastric pain.

Why Manufacturers Choose Domperidone

Domperidone is one of the most widely prescribed gastroprokinetic agents globally, with high demand across gastroenterology, general practice, and palliative care. It is available as 10mg tablets, oral suspension, and suppositories, providing a versatile product line for PCD franchise partners. The molecule is included in the WHO Model List of Essential Medicines and enjoys strong prescription volumes for chronic conditions such as gastroparesis and functional dyspepsia. Indian manufacturers produce domperidone as a standalone product and as part of fixed-dose combinations with pantoprazole, omeprazole, and ranitidine for comprehensive GERD and dyspepsia management. Well-established API supply chains, cost-effective manufacturing processes, and compliance with IP, BP, and USP standards make domperidone a high-volume molecule for third-party manufacturing and export to regulated markets including the UK, Europe, and Asia.

This makes Domperidone a staple molecule for third party manufacturing in India, with consistent demand from PCD franchise networks and export channels.